TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet

Core Insights - TransThera Sciences Inc. announced the publication of clinical results from a Phase 2 trial of tinengotinib for Cholangiocarcinoma (CCA) in a prestigious medical journal [1][5] Group 1: Clinical Trial Results - The Phase 2 trial (NCT04919642) included patients with FGFR2 fusion-positive CCA who had primary or acquired resistance to prior FGFR inhibitor therapy, as well as those with other FGFR alterations [3] - Tinengotinib showed clinical activity in patients with FGFR2 fusion-positive CCA with acquired FGFR inhibitor resistance and in other FGFR-altered subtypes [3][4] Group 2: Expert Commentary - Dr. Milind Javle emphasized the need for next-generation FGFR inhibitors to overcome resistance, highlighting tinengotinib's design to inhibit both FGFR and compensatory pathways [4] - Dr. Jean Fan noted the significance of the trial results and their recognition in a leading journal, indicating the potential for tinengotinib to provide new treatment options for patients with refractory CCA [5] Group 3: Drug Profile - Tinengotinib is a multi-kinase inhibitor targeting FGFRs, VEGFRs, and other kinases, showing promise in various solid tumors [6] - The drug has received multiple designations from regulatory bodies, including Orphan Drug Designation and Fast Track Designation from the FDA for CCA treatment [6] Group 4: Company Overview - TransThera is focused on developing innovative small molecule therapies for oncology and other diseases, aiming to meet urgent clinical needs globally [7]